Journal of Immunology Research / 2015 / Article / Fig 2

Clinical Study

Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients

Figure 2

Immune response and overall survival. Association between immune responses and OS was examined with the Kaplan-Meier method, and a comparison of the survival curves was performed with the log-rank test. (a) The peptide-specific IgG1 response was potentially prognostic ( by log-rank test, by Wilcoxon test); all 6 patients showing increased IgG1 responses to both the C-35 peptide and TAA-derived peptides survived more than 210 days, and their MST (286 days) tended to be longer than that of patients showing increased IgG1 responses to either peptide (162 days) or that of patients showing no increase to any peptide (223 days). (b) The peptide-specific IgG response was not prognostic (). (c) The peptide-specific IgG2 response was not prognostic (). (d) The peptide-specific CTL response was not prognostic ().
(a)
(b)
(c)
(d)

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.